1 |
Crystal structures of dimethylarginine dimethylaminohydrolase-1 (DDAH-1) from Homo sapiens bound to the inhibitors N⁵-(1-iminopentyl)-L-ornithine and ebselen and functional studies of the translin●trax complex from Mus musculusLluis, Matthew Wayne 23 August 2010 (has links)
Nitric oxide (NO) is reactive, radical gas that is involved in a myriad of cellular signaling pathways including the regulation of blood flow and immunodefense. NO is produced from the oxidation of L-arginine to L-citrulline by nitric oxide synthase (NOS). The activity of NOS and by default, the production of NO, is regulated by the arginine derivatives N[omega],N[omega]-dimethyl-L-arginine (ADMA) and N[omega]-monomethyl-L-arginine (NMMA) which arise from the proteolytic degradation of post translationally methylated proteins. The cellular concentrations of ADMA and NMMA are regulated by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), which catabolizes these compounds to L-citrulline and dimethylamine or methyl amine, respectively. Because over and under production of NO has been implicated in several pathophysiological states, compounds that control NO production by inhibiting NOS or DDAH may prove useful as treatments. In this study, the crystal structures of human DDAH-1 with the inhibitors N⁵-(1-iminopentyl)-L-ornithine (L-IPnO) and ebselen were solved to 2.9 and 2.0 Å resolution, respectively. L-IPnO was observed to inhibit DDAH-1 in essentially the same manner as another amidino-containing inhibitor: docking to the enzyme via hydrogen bond and ion pair interactions and forming a covalent adduct with the active site cysteine. Ebselen was also observed to covalently attach to the active site cysteine, however, the docking mechanism was absent of hydrogen bond and ion pair interactions. The work presented here contributes to the design of compounds that may effectively regulate the production of NO for therapeutic purposes.
Translin is a highly conserved mammalian RNA and DNA binding protein known to be involved in DNA recombination and repair, RNA trafficking in neurons, and post-transcriptional regulation of gene expression in male germ cells. Although crystal structures of the mouse and human orthologs of translin have been solved, they do not provide details on the structure-function relationship of the protein. Studies have identified a partner protein for translin, translin associated factor x (trax), which is believed to have a crucial role in assisting translin with its cellular functions. It is believed that trax regulates translin’s affinity for certain RNA and DNA sequences. In this work the binding affinities of translin and the translin●trax complex were investigated. It was observed that translin preferentially binds to G-rich RNA sequences, most likely recognizing a secondary structure intrinsic to these sequences, whereas translin●trax preferentially binds G-rich DNA sequences. The results from these experiments provide insight into the cellular functions of translin and trax and their respective roles in mRNA trafficking. / text
|
2 |
Asymetrický dimethylarginin a jeho vztah k aterogenezi / Asymmetric Dimethylarginine and Its Relation to AtherogenesisŠiroká, Romana January 2007 (has links)
ASYMMETRIC DIMETHYLARGININE - COMPARSION OF CHROMATOGRAPHY AND IMMUNOMETRIC METHODS Objective:Asymmetric dimethylarginine (ADMA) is often discussed in connection with hyperhomocysteinemia and its toxic effect on vessel wall. ADMA concentration is usually measured by HPLC (High Performance Liquid Chromatography) after previous derivatisation. Recently, ELISA (Enzym Linked Immuno Assay) methods for ADMA determination were introduced and ELISA kits are commercially available. Method and Result:The aim of the study was to compare HPLC and ELISA methods for ADMA determination. For HPLC determination we used equipments from Thermo separation product (Florida, USA). After solid-phase extraction on polymer cation-exchange column and the following derivatisation with o-phthaldialdehyde the samples were separated using C18 column (mobile phase 8.7% acetonitril, 50 mmol/l phosphate buffer, pH 6.5) and a fluorescence detector. NG-monomethyl-L-arginine was used as an internal standard. ADMA® ELISA kit, based on a competitive principle, was obtained from DLD Diagnostika, Hamburg, Germany. ADMA was measured in EDTA plasma of 40 healthy blood donors and 40 hemodialysis patients with hyperhomocysteinemia. Conclusion: In spite of different principles both methods showed a very good correlation (r = 0.944, p<0.0001). ELISA...
|
3 |
Symmetric dimethylarginine: a novel renal biomarkerGuess, Sarah Crilly January 1900 (has links)
Master of Science / Biomedical Sciences / Gregory F. Grauer / Chronic kidney disease (CKD) is a potentially life-threatening disease that reportedly affects 10% of dogs and 30% of cats over the age of 15. There is no cure available for CKD, but medical management is available for patients with this disease. Research has focused on earlier detection of CKD with the goal of instituting medical management and monitoring as early in the disease course as possible. Symmetric dimethylarginine (SDMA) has recently emerged as a novel renal excretory biomarker that may aid in early detection of CKD in cats and dogs. SDMA is non-protein bound and is freely filtered by the glomerulus, is not secreted or reabsorbed, and has greater than 90% excretion by the kidneys, making it a potential target for measurement of glomerular filtration rate (GFR). Previous studies have demonstrated a close parallel between SDMA and serum creatinine (sCr), which is the currently favored serum biomarker for assessment of GFR. Research has also demonstrated a correlation between SDMA and GFR. Serum concentrations of SDMA increase above normal when GFR is decreased by 25-40%; much earlier than the 75% decrease in GFR typically required for sCr to increase above its reference interval. The studies reported here demonstrate a potential use for the SDMA:sCr ratio as a predictor of volume responsive azotemia. Furthermore, longitudinal assessment of older dogs and cats for early detection of CKD showed that SDMA was a more sensitive indicator of CKD than sCr. The evaluation of SDMA reported in this thesis presents a novel perspective on SDMA and its use clinically.
|
4 |
Studies on the mechanism and inhibition of enzymes in the pentein superfamilyLinsky, Thomas W. 13 November 2013 (has links)
Dimethylarginine dimethylaminohydrolase (DDAH) indirectly regulates nitric oxide production by hydrolyzing methylated arginines, which are endogenous nitric oxide synthase inhibitors. This enzyme is a member of the mechanistically diverse pentein superfamily, which contains hydrolase, dihydrolase, and amidinotransferase enzymes. These enzymes are proposed to use the same first catalytic step, followed by partitioning into their respective activities. Here, variants of DDAH that can catalyze the dihydrolase and amidinotransfer reactions are presented, as well as a variant of succinylarginine dihydrolase which catalyzes a single hydrolysis reaction. The results experimentally demonstrate that the proposed common catalytic intermediate can be used for several different reactions. The results suggest that enzymes in the pentein superfamily may have evolved divergently from a catalytically promiscuous ancestor. The control DDAH asserts over nitric oxide production makes it an attractive drug target for disease states marked by pathological overproduction of nitric oxide. Only a limited number of inhibitors different from substrate are reported, due in part to lack of robust assays for high-throughput screening of compound libraries. Therefore, high-throughput assays were developed, optimized, and validated to screen for inhibitors of Pseudomonas aeruginosa DDAH and human DDAH-1. These assays were used to screen three commercial libraries totaling 6,466 compounds. One drug in phase III clinical trials, ebselen, was identified and characterized as a bioavailable, rapid covalent inactivator of DDAH both in vitro and in cultured cells. Four "fragment-sized" inhibitors were also identified and characterized in the screening, including 4-halopyridines and benzimidazole-like compounds. The 4-halopyridines, not previously known to modify proteins, act as quiescent affinity labels to selectively inactivate DDAH, and the benzimidazole-like compounds are competitive, rapidly reversible inhibitors of DDAH. These diverse molecules serve as starting points for the development of molecular probes and therapeutic drugs to reduce pathological overproduction of nitric oxide. / text
|
5 |
O papel dos genes DDAH1 e DDAH2 sobre o risco para desenvolvimento de disfunção erétil / The role of the DDAH1 and DDAH2 genes on the risk for developing erectile dysfunctionAnselmi, Guilhermo Brites 22 November 2018 (has links)
Uma das principais causas da disfunção erétil (DE) pode ser relacionada com o déficit de óxido nítrico (NO) no corpo humano. O principal componente para a produção do NO é o aminoácido L-arginina que é utilizado pelas enzimas óxido nítrico sintase neuronal (nNOS), endotelial (eNOS) e induzida (iNOS) para sua produção. A dimetilarginina assimétrica (ADMA) atua como inibidor endógeno dos três subtipos de NOS citadas acima e é metabolizada pelas enzimas dimetilarginina dimetilaminohidrolase 1 e 2 (DDAH1 e DDAH2). Diversos estudos têm relacionado a alteração na expressão ou atividade das enzimas DDAH bem como alterações em seus genes, com distúrbios onde a sinalização de NO é prejudicada. Os objetivos deste estudo foram investigar a associação de variantes genéticas dos genes DDAH1 (rs1554597 e rs18582) e DDAH2 (rs805304 e 805305) com a predisposição à disfunção erétil (DE), scores de função erétil e concentrações plasmáticas de nitrito e ADMA. Também verificar se estes marcadores bioquímicos estão relacionados aos scores de função erétil. Foram selecionados 130 pacientes com DE clínica e 98 participantes controles saudáveis sem DE. A função erétil dos voluntários foi avaliada através do questionário Índice Internacional de Função Erétil (IIEF). Os genótipos dos rs1554597, rs805304 e rs805305 foram obtidos através da técnica de reação em cadeia da polimerase (PCR) seguida de digestão enzimática, e do rs18582 apenas por técnica de PCR alelo específica. No grupo Pacientes, foram encontradas associações do gene DDAH1 com as concentrações plasmáticas de ADMA: o rs1554597 teve os genótipos TT e TC associados positivamente (TT: ? 0,13 e P = 0,008; TC: ? 0,09 e P = 0,016;) e o genótipo CC associado negativamente (? -0,22 e P <0,001); já o rs18582 teve o genótipo GG associado positivamente (? 0,22 e P <0,001) e o genótipo AA associado negativamente (? -0,16 e P = 0,001); o haplótipo TG foi associado positivamente (? 0,12 e P = 0,016) e o haplótipo CA negativamente (? -0,18 e P = 0,002). Com relação ao nitrito, associações dos haplótipos do gene DDAH2 foram encontradas, o haplótipo CC foi associado negativamente (? -0,03 e P = 0,045) e o haplótipo AG foi associado positivamente (? 0,03 e P = 0,045).O rs18582 teve o genótipo GG associado positivamente com as concentrações plasmáticas de nitrito, no modelo aditivo (? 0,15 e P = 0,009) e no modelo dominante (? 0,08 e P = 0,009), e os genótipos GA ou AA associados negativamente com as concentrações plasmáticas de nitrito, apenas no modelo dominante (? -0,08 e P = 0,009). Não foi encontrada nenhuma outra associação significativa no estudo / One of the main causes for erectile dysfunction (ED) is related to nitric oxide (NO) deficiency in human body. The main substrate for NO synthesis is the amino acid L-arginine, which is processed by NO synthases (NOS) from three subtypes for its production: neuronal (nNOS), endothelial (eNOS) and inducible (iNOS). Asymmetric Dimethylarginine (ADMA) acts as an endogenous inhibitor of the three subtypes of NOS and is metabolized by enzymes dimethylarginine dimethylaminohydrolase types 1 and 2 (DDAH1 and DDAH2). Several studies associate the altered expression or activity of DDAH enzymes, as well as their genes, with diseases with hampered NO signaling. The objectives of this study were to investigate the association of genetic variants of DDAH1 (rs1554597 and rs18582) and DDAH2 (rs805304 and 805305) with vulnerability to develop ED, with altered scores of erectile function and with altered plasma concentrations of nitrite and ADMA. We also investigated whether these biochemical markers associated with erectile function scores and ED risk. We selected 130 patients with clinical ED and 98 healthy controls without ED. Erectile function was assessed through the International Index for Erectile Function (IIEF) questionnaire. Genotypes for rs1554597, rs805304 and rs805305 were obtained with polymerase chain reaction (PCR) followed by enzyme restriction (RFLP), while rs18582 was determined using Allele-Specific oligonucleotide PCR (ASO-PCR). At patients group, we found association of variants in DDAH1 gene with plasma ADMA levels: TT and TC genotypes of rs1554597 were associated with increases in ADMA (TT: ? 0.13 e P = 0.008; TC: ? 0.09 e P = 0.016;), while CC genotype was associated with decreases in ADMA (? 0.22 e P <0.001); regarding rs18582, GG genotype associated with increases in ADMA (? 0.22 e P <0.001), while AA genotype associated negatively (? -0.16 e P = 0.001); besides, haplotype TG was also associated with ADMA increases (? 0.12 e P = 0.016), while CA haplotype associated negatively with ADMA levels (? -0.18 e P = 0.002). Regarding nitrite, associations of the haplotypes of the DDAH2 gene were found, the haplotype CC was negatively associated (? -0,03 and P = 0,045) and the haplotype AG was positively associated (? 0,03 and P = 0,045) .O rs18582 had the GG genotype positively associated with plasma nitrite concentrations in the additive model (? 0.15 and P = 0.009) and in the dominant model (? 0.08 and P = 0.009), and negatively associated genotypes GA or AA with plasma nitrite concentrations, only in the dominant model (? -0.08 and P = 0.009). We found no further significant associations in our study
|
6 |
Marcadores de resposta ao sildenafil no tratamento da disfunção erétil: genes relacionados à dimetilarginina assimétrica / Markers of sildenafil responsiveness in the treatment of erectile dysfunction: asymmetric dimethylarginine related genesAzevedo, Ana Maria Milanez 10 March 2017 (has links)
A disfunção erétil (DE) é uma doença relacionada com a sinalização deficiente de óxido nítrico (NO). O NO é produzido a partir da L-arginina pelas enzimas óxido nítrico sintase neuronal (nNOS), endotelial (eNOS) e induzida (iNOS). A dimetilarginina assimétrica (ADMA) é um inibidor endógeno dos três subtipos existentes de NOS, e é metabolizada principalmente pelas enzimas dimetilarginina dimetilaminohidrolase 1 e 2 (DDAH1 e DDAH2). Vários estudos têm associado alterações em genes, expressão ou atividade das enzimas DDAH com distúrbios em que a sinalização de NO é prejudicada. O objetivo deste estudo foi avaliar se o nível de resposta ao tratamento da DE com sildenafil pode estar associado a polimorfismos dos genes DDAH1 (rs1554597 e rs18582) e DDAH2 (rs805304 e rs805305) e, também, aos haplótipos formados por estes polimorfismos. Foram selecionados 70 pacientes com DE pós-prostatectomia (DEPP) e 70 pacientes com DE clínica (DEC). A função erétil dos voluntários foi avaliada através do questionário Índice Internacional de Função Erétil (IIEF). Para avaliação da resposta ao sildenafil, foram calculadas a diferença entre as pontuações pré e pós-tratamento (?IIEF) e a percentagem atingida da máxima resposta possível (?IIEF%) de cada paciente. Também, os pacientes de cada grupo foram divididos em bons e maus respondedores ao sildenafil de acordo com a mediana dos valores de ?IIEF%. Os genótipos dos rs1554597, rs805304 e rs805305 foram obtidos pela técnica de reação em cadeia da polimerase (PCR) seguida de digestão enzimática, e do rs18582 pela técnica de PCR alelo específica. O software PHASE 2.1 foi utilizado para estimar os haplótipos em cada grupo. Os resultados mostraram que o alelo variante A do rs18582 apresentou tendência para associação com piores respostas ao sildenafil no grupo DEC (P=0,058). No grupo DEPP, portadores dos alelos variantes A do rs805304 e G do rs805305 foram associados a melhores respostas ao sildenafil (?IIEF, P=0,007; ?IIEF%, P=0,025; e score IIEF pós-tratamento, P=0,014). Não foram encontradas outras associações significativas. Estes resultados mostram que os marcadores genéticos rs805304 e rs805305 do DDAH2 podem influenciar as respostas ao sildenafil em pacientes com DE. / Erectile dysfunction (ED) is a disease related to deficient nitric oxide (NO) signaling. NO is produced from L-arginine by three isoforms of the enzyme nitric oxide synthase: neuronal (nNOS), endothelial (eNOS) and induced (iNOS). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of the three existing NOS subtypes, and is metabolized primarily by dimethylarginine dimethylaminohydrolase 1 and 2 (DDAH1 and DDAH2) enzymes. Several studies have associated changes in genes, expression or activity of DDAH enzymes with disorders in which NO signaling is impaired. The aim of this study was to evaluate whether the response to ED treatment with sildenafil may be associated with polymorphisms of the DDAH1 (rs1554597 and rs18582) and DDAH2 genes (rs805304 and rs805305), as well as the haplotypes formed by these polymorphisms. We selected 70 patients with postprostatectomy ED (PPED) and 70 patients with clinical ED (CED). The erectile function of the volunteers was assessed using the International Index for Erectile Function (IIEF) questionnaire. To evaluate the response to sildenafil, the difference between the pre- and post-treatment scores (?IIEF) and the percentage reached from the maximum possible response (?IIEF%) of each patient were calculated. Also, patients from each group were divided into good and bad responders to sildenafil according to the median values of ?IIEF%. The genotypes of rs1554597, rs805304 and rs805305 were obtained by the polymerase chain reaction (PCR) technique followed by enzymatic digestion, and rs18582 by the allele-specific PCR technique. The PHASE 2.1 software was used to estimate the haplotypes in each group. The results showed that the variant A allele of rs18582 showed a tendency to be associated with a greater chance of worse responses to sildenafil in the DEC group (P=0,058). In the DEPP group, carriers of the variant alleles A of rs805304 and G of rs805305 were associated with better responses to sildenafil (?IIEF, P=0,007; ?IIEF%, P=0,025; and post-treatment IIEF score, P=0,014). No other significant associations were found. These results show that the genetic markers rs805304 and rs805305 of DDAH2 may influence the responses to sildenafil in patients with ED.
|
7 |
Marcadores de resposta ao sildenafil no tratamento da disfunção erétil: genes relacionados à dimetilarginina assimétrica / Markers of sildenafil responsiveness in the treatment of erectile dysfunction: asymmetric dimethylarginine related genesAna Maria Milanez Azevedo 10 March 2017 (has links)
A disfunção erétil (DE) é uma doença relacionada com a sinalização deficiente de óxido nítrico (NO). O NO é produzido a partir da L-arginina pelas enzimas óxido nítrico sintase neuronal (nNOS), endotelial (eNOS) e induzida (iNOS). A dimetilarginina assimétrica (ADMA) é um inibidor endógeno dos três subtipos existentes de NOS, e é metabolizada principalmente pelas enzimas dimetilarginina dimetilaminohidrolase 1 e 2 (DDAH1 e DDAH2). Vários estudos têm associado alterações em genes, expressão ou atividade das enzimas DDAH com distúrbios em que a sinalização de NO é prejudicada. O objetivo deste estudo foi avaliar se o nível de resposta ao tratamento da DE com sildenafil pode estar associado a polimorfismos dos genes DDAH1 (rs1554597 e rs18582) e DDAH2 (rs805304 e rs805305) e, também, aos haplótipos formados por estes polimorfismos. Foram selecionados 70 pacientes com DE pós-prostatectomia (DEPP) e 70 pacientes com DE clínica (DEC). A função erétil dos voluntários foi avaliada através do questionário Índice Internacional de Função Erétil (IIEF). Para avaliação da resposta ao sildenafil, foram calculadas a diferença entre as pontuações pré e pós-tratamento (?IIEF) e a percentagem atingida da máxima resposta possível (?IIEF%) de cada paciente. Também, os pacientes de cada grupo foram divididos em bons e maus respondedores ao sildenafil de acordo com a mediana dos valores de ?IIEF%. Os genótipos dos rs1554597, rs805304 e rs805305 foram obtidos pela técnica de reação em cadeia da polimerase (PCR) seguida de digestão enzimática, e do rs18582 pela técnica de PCR alelo específica. O software PHASE 2.1 foi utilizado para estimar os haplótipos em cada grupo. Os resultados mostraram que o alelo variante A do rs18582 apresentou tendência para associação com piores respostas ao sildenafil no grupo DEC (P=0,058). No grupo DEPP, portadores dos alelos variantes A do rs805304 e G do rs805305 foram associados a melhores respostas ao sildenafil (?IIEF, P=0,007; ?IIEF%, P=0,025; e score IIEF pós-tratamento, P=0,014). Não foram encontradas outras associações significativas. Estes resultados mostram que os marcadores genéticos rs805304 e rs805305 do DDAH2 podem influenciar as respostas ao sildenafil em pacientes com DE. / Erectile dysfunction (ED) is a disease related to deficient nitric oxide (NO) signaling. NO is produced from L-arginine by three isoforms of the enzyme nitric oxide synthase: neuronal (nNOS), endothelial (eNOS) and induced (iNOS). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of the three existing NOS subtypes, and is metabolized primarily by dimethylarginine dimethylaminohydrolase 1 and 2 (DDAH1 and DDAH2) enzymes. Several studies have associated changes in genes, expression or activity of DDAH enzymes with disorders in which NO signaling is impaired. The aim of this study was to evaluate whether the response to ED treatment with sildenafil may be associated with polymorphisms of the DDAH1 (rs1554597 and rs18582) and DDAH2 genes (rs805304 and rs805305), as well as the haplotypes formed by these polymorphisms. We selected 70 patients with postprostatectomy ED (PPED) and 70 patients with clinical ED (CED). The erectile function of the volunteers was assessed using the International Index for Erectile Function (IIEF) questionnaire. To evaluate the response to sildenafil, the difference between the pre- and post-treatment scores (?IIEF) and the percentage reached from the maximum possible response (?IIEF%) of each patient were calculated. Also, patients from each group were divided into good and bad responders to sildenafil according to the median values of ?IIEF%. The genotypes of rs1554597, rs805304 and rs805305 were obtained by the polymerase chain reaction (PCR) technique followed by enzymatic digestion, and rs18582 by the allele-specific PCR technique. The PHASE 2.1 software was used to estimate the haplotypes in each group. The results showed that the variant A allele of rs18582 showed a tendency to be associated with a greater chance of worse responses to sildenafil in the DEC group (P=0,058). In the DEPP group, carriers of the variant alleles A of rs805304 and G of rs805305 were associated with better responses to sildenafil (?IIEF, P=0,007; ?IIEF%, P=0,025; and post-treatment IIEF score, P=0,014). No other significant associations were found. These results show that the genetic markers rs805304 and rs805305 of DDAH2 may influence the responses to sildenafil in patients with ED.
|
8 |
An investigation of the irreversible inhibition of human N[superscript ω], N[superscript ω]- dimethylarginine dimethylaminohydrolase (DDAH1)Burstein, Gayle Diane 10 September 2015 (has links)
Nitric oxide synthases (NOS) are responsible for the production of nitric oxide (NO), an essential cell-signaling molecule, in mammals. There are three isoforms of NOS with widely different tissue distribution. The overproduction of NO is marked in many human disease states and cancers, however due to the similarities of the enzyme isoforms, targeting NOS for inhibition has proven challenging. Endogenously, the methylated arginines, N[superscript ω]-monomethyl-L-arginine (NMMA) and asymmetric N[superscript ω], N[superscript ω]-dimethyl-L-arginine (ADMA), inhibit NOS. N[superscript ω], N[superscript ω]-Dimethylarginine dimethylaminohydrolase (DDAH1) metabolizes these methylated arginines and thus relieves NOS inhibition. The role of DDAH1 in the regulation of diseases such as cancer and septic shock is still being elucidated. It is thought that targeting DDAH1 for inhibition rather than NOS may circumvent many of the current problems with the treatment of NO overproduction such as isoform selectivity. My PhD studies focus on the synthesis of a series of irreversible inhibitors of DDAH1, an extensive study of their in vitro mode of inhibition, a comparison of analytical fitting methods, and the viability and efficacy of the inactivators in a human cell line. I also studied a potential endogenous inactivator of DDAH1, nitroxyl (HNO), a one-electron reduction product of NO. / text
|
9 |
Marqueurs du métabolisme du fer et dérivés de la L-arginine dans la cardiopathie ischémique : mise en évidence, intérêt de leur évaluation et rôle du stress oxydant en phase aiguë d’infarctus du myocarde / Iron metabolism markers and l-arginine derivatives in coronary artery disease : highlighting, assessment and role of oxidative stress in acute myocardiae infarctionGudjoncik, Aurélie 23 December 2015 (has links)
L’infarctus du myocarde (IDM) résulte des complications de l’athérosclérose, dont le développement serait initié par une dysfonction endothéliale, s’accompagnant d’un état de stress oxydant. Le fer interagirait dans cette pathogenèse à différents niveaux et aurait également un rôle majeur dans la survenue de la dysfonction endothéliale. L’hepcidine et l’érythroferrone (découverte auparavant sous le nom de myonectine/CTRP 15), participeraient dans la régulation de certaines étapes du métabolisme du fer. La diméthyl-arginine asymétrique (ADMA), marqueur de dysfonction endothéliale, est associée à la plupart des facteurs de risque cardiovasculaire. Son stéréo-isomère, la diméthyl-arginine symétrique (SDMA), a une élimination exclusivement rénale et est considéré comme un puissant marqueur de fonction rénale.Nous nous sommes proposés d’étudier, chez des patients en phase aiguë d’IDM, la signification des paramètres traditionnels du statut du fer, des protéines impliquées dans la régulation du fer, l’hepcidine et la myonectine, ainsi que des dérivés méthylés de la L-arginine, l’ADMA et la SDMA.Dans notre première étude prospective, nous observons que les valeurs de SDMA, et dans une moindre mesure celles d'ADMA, sont associées à la glycémie d'admission et pourraient donc exercer des actions biologiques indépendantes de la fonction rénale. Notre second travail suggère que les patients présentant de l’insuffisance cardiaque à la phase aiguë de l’IDM sont caractérisés par une anémie et un certain degré de carence en fer. Le dosage des nouveaux biomarqueurs de la régulation du métabolisme du fer, l'hepcidine et la myonectine a montré une tendance à l’augmentation de ces taux sériques chez ces patients en lien avec une augmentation de la CRP. Ainsi nos travaux laissent entrevoir les liens qui uniraient, à la phase aiguë de l’infarctus du myocarde, ces nouveaux biomarqueurs régulateurs du métabolisme du fer aux conséquences fonctionnelles des pathologies cardiovasculaires, notamment en termes d’anémie et d’insuffisance cardiaque. / Myocardial infarction (MI) is mostly caused by complications of atherosclerosis, whose the development would be initiated by a dysfunction of the vascular endothelium, characterized by an inflammatory condition and oxidative stress.In this pathogenesis, iron interacts at different levels and also has a major role in the development of endothelial dysfunction. Hepcidin and erythroferrone (discovered earlier as the myonectin/CTRP 15) participate in a major way in regulating certain stages of iron metabolism.Asymmetric dimethylarginine (ADMA), a marker of endothelial dysfunction is associated with most cardiovascular risk factors. Symmetrical dimethyl-arginine (SDMA), its stereoisomer, has an exclusively renal elimination and is considered as a powerful renal function marker.We aimed to study, in patients with acute MI, the meaning of the "traditional" status iron parameters, two proteins involved in the regulation of iron, hepcidin and myonectin, as well as the two L-arginine derivatives, ADMA and SDMA. In our first prospective study, we observe that, in patients with acute MI, the values of SDMA, and only weakly ADMA, are associated with admission blood glucose, beyond traditional dimethylarginine determinants and may therefore have biological activity beyond renal function.Our second work suggests that patients with heart failure in the acute phase of MI present more frequently anemia and a certain degree of iron deficiency. New iron metabolism regulators biomarkers, hepcidin and myonectin showed a trend toward an increase in the serum levels in these patients characterized by an increase in CRP.Thus, our work suggests the links between these new regulators of iron metabolism in acute MI with functional consequences of cardiovascular diseases, particularly in terms of anemia and heart failure.
|
10 |
La régulation de la perfusion musculaire dépendante du monoxyde d’azote (NO) : effet de l’aptitude aérobie et des facteurs de risques cardiovasculaires liés à la diméthylarginine asymétrique / Regulation of nitric oxide (NO) -mediated blood flow to muscles : effect of aerobic fitness and cardiovascular risk factors related to Asymmetric Dimethylarginine (ADMA)Pawlak-Chaouch, Mehdi 11 December 2017 (has links)
Ce projet de thèse avait pour objet d’étudier la régulation de la biodisponibilité du monoxyde d’azote (NO) à travers la supplémentation en nitrate (NO3-) chez l’homme, et la perfusion d’ADMA chez l’animal. Nous avons essayé de déterminer les répercussions de la modulation de la biodisponibilité du NO sur la perfusion musculaire à l’exercice, et l’effet de l’aptitude aérobie sur cette modulation. Dans notre méta-analyse, nous avons rapporté une diminution de la consommation d’oxygène (V̇O2) lors d’exercices d’intensité modérée à élevée, avec une amélioration de la tolérance à l’exercice sans réduction du V̇O2 chez les sujets présentant une pathologie. Dans une seconde étude, aucune amélioration de la tolérance à l’effort n’a été observée chez des athlètes [consommation maximale d’oxygène (V̇O2max) > 65 mL.min-1.kg-1] au cours d’un exercice intermittent d’intensité supramaximale après une supplémentation en NO3- et sans modification au niveau du V̇O2 et de la perfusion musculaire. Une troisième étude montre que l’aptitude aérobie et l’apport en O2 aux muscles, dépendante de la perfusion musculaire, ne sont pas associés à la concentration plasmatique d’ADMA chez des sujets jeunes et sains. Enfin, notre quatrième étude ne rapporte pas d’effet de la perfusion de l’ADMA sur la perfusion musculaire au cours d’un exercice de course chez des rats. En conclusion, la supplémentation en NO3- peut contribuer à une amélioration de la performance à travers une réduction du coût en O2 pour des exercices sous-maximaux. Cependant, les sujets entraînés en endurance avec une aptitude aérobie élevée ne présentent ni d’effet ergogénique, ni d’amélioration de la perfusion musculaire à la suite d’une supplémentation en NO3- lors d’exercices intermittents supramaximaux, contrairement aux sujets modérément entraînés. En outre, l’ADMA, en tant inhibiteur de la synthèse du NO, ne semble pas jouer un rôle dans la régulation du débit sanguin et de l’apport en O2 aux muscles actifs, en l’absence de conditions pathologiques. / We aimed to determine whether dietary nitrate (NO3-) supplementation and ADMA modulate NO bioavailability and muscle blood flow during exercise. The second purpose was to establish whether aerobic fitness alters the effects of dietary NO3- supplementation and ADMA on muscle blood flow during exercise. In our meta-analysis, we found that dietary NO3- supplementation decreases V̇O2 during exercise performed in the moderate and heavy intensity domains in healthy subjects, and enhances exercise tolerance in subjects with chronic diseases, but no change in V̇O2. Our second study showed that dietary NO3- supplementation did not increase the number of repetitions completed during supramaximal intensity intermittent exercise in endurance athletes with high aerobic fitness (V̇O2max > 65 mL.kg-1.min-1), and did not increase muscle blood volume. In the third study, aerobic fitness is not related to muscle O2 delivery and plasma ADMA concentrations in young male subjects with a wide range of aerobic fitness level. In the fourth study, increased plasma ADMA levels did not decrease muscle blood flow during low-treadmill running exercise in healthy rats. In conclusion, dietary NO3- supplementation could contribute to an improved tolerance to exercise by reducing O2 cost during exercises at submaximal intensities. However, endurance-trained athletes with high V̇O2max level do not benefit from the effects of dietary NO3- supplementation on exercise performance and muscle blood flow as reported in moderately trained subjects. Moreover, ADMA did not regulate muscle blood flow and O2 delivery during exercise in conditions free from cardiovascular and metabolic diseases in humans and in the rat with pharmacological-induced increase in plasma ADMA levels.
|
Page generated in 0.0806 seconds